Brief: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
11/08/2026 21:51
BRIEF-MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program Aug 11 (Reuters) - Gilead Sciences, Inc GILD.O:
MACROGENICS - GILEAD SCIENCES EXERCISES OPTION FOR EXCLUSIVE LICENSE FOR A PRECLINICAL BISPECIFIC PROGRAM, TRIGGERS $10 MILLION PAYMENT TO MACROGENICS
MACROGENICS - REMAINS ELIGIBLE TO RECEIVE UP TO APPROXIMATELY $1.6 BILLION IN ADDITIONAL DEVELOPMENT
Source text: ID:nGNE1HzNyN
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MacroGenics
See all newsMacroGenics Inc reports results for the quarter ended June 30 - Earnings Summary
MacroGenics Q2 revenue misses estimates, posts profit on asset sale
Brief: MacroGenics Q2 Net Income USD 19.5 Million
MacroGenics rises on $10 million milestone payment from Gilead
Brief: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program